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Volume 6Available online xxxBackground: Immune checkpoint inhibitors (ICIs) treatment is a breakthrough in managing metastatic solid tumours,
but its use is associated with a high financial burden for public health care systems. Validated tools such as the
European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) are frameworks that
might help to better assess the clinical benefit of these novel innovative cancer drugs.
Methods: Here, we systematically analysed the number of European Medicines Agency-approved ICIs labels with an
ESMO-MCBS grade <4 and the impact of the ICIs on incremental costs, gain of life years (LYs), quality-adjusted life
years (QALYs) and the incremental cost-effectiveness ratio in the Austrian population.
Results: Of 23 ICIs treatment settings, we identified three clinical scenarios in metastatic solid cancers with an ESMO-
MCBS grade <4 with no otherwise approved alternatives. In triple-negative breast cancer (TNBC), the addition of first-
line atezolizumab increased QALYs by 0.33 compared with nab-paclitaxel only, with an incremental cost per QALY of
V143 853. In small-cell lung cancer (SCLC), the addition of first-line atezolizumab increased the QALY by 0.09, with
an incremental cost per QALY of V373 256, and the addition of first-line durvalumab increased the QALYs by 0.11,
with an incremental cost per QALY of V589 527.
Conclusions: Overall, most of the approved ICIs carry significant clinical benefit (4). Although TNBC and SCLC are
challenging treatment scenarios, currently approved ICIs with an ESMO-MCBS grade <4 substantially increase the
cost of medical treatment, and under a willingness-to-pay threshold of V100 000, they do not have a cost-effective
comparative benefit.
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Immune checkpoint inhibition through monoclonal anti-
bodies has revolutionized treatment across multiple types
of cancer, enabling oncologists to envision potentially long-
term disease stabilization approaches even in metastatic
solid tumours.1 Although this advance in efficacy is
encouraging, in addition to serious side-effects of these
drugs, the financial burden (or financial toxicity) of immune
checkpoint inhibitors (ICIs) clearly shows increasing expen-
ditures, with annual treatment costs exceeding V100 000ondence to: Dr Martin Pichler, Division of Oncology, Medical
of Graz, Auenbruggerplatz 25, 8010 Graz, Austria. Tel: þ43-316385-
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- Issue 4 - 2021per patient.2 In addition, the reported efficacy of ICIs varies
substantially between different types of cancer. While the
introduction of ICIs has tremendously increased the 5-year
overall survival (OS) rate of patients with certain types of
cancer (e.g. metastatic melanoma patients now carry a 5-
year OS rate of 52%),3 other ICIs approvals are based
solely on rather small clinical benefits (e.g. for small-cell
lung cancer (SCLC), an improvement in OS of w2 months
led to drug approval).4 Given the high economic burden of
novel cancer drugs, especially ICIs, different cancer organi-
zations, health care providers and insurance companies
have gained more interest in quantitatively assessing the
clinical benefit of these novel cancer drugs.5 To date,
frameworks to evaluate novel innovative cancer drugs have
been developed by several meaningful international cancer
societies, including the American Society of Clinical
Oncology (ASCO) Value Framework (AVF) and the European
Society for Medical Oncology-Magnitude of Clinical Benefit
Scale (ESMO-MCBS).6,7https://doi.org/10.1016/j.esmoop.2021.100198 1
ESMO Open M. Pichler & J. SteyrerThe ESMO-MCBS was originally launched in 20157 and
revised in 2017 to the ESMO-MCBS version 1.1.8 The ESMO
scale aims to provide a globally validated and rational
stratification tool for innovative, cost-intensive cancer
drugs, with the mission of ‘accountability for reasonable-
ness’, which incorporates extensive field testing and the
peer review of results for ‘reasonableness’.7 As value is
based on considerations of the magnitude of clinical benefit
as well as costs and confronted with the challenges of un-
derstanding the actual magnitude of the clinical benefit, the
ESMO-MCBS was developed as a validated and reproducible
scale that is applicable across the full range of solid tumours
in oncology.7 The scoring criteria of the ESMO-MCBS
comprise five different evaluation forms depending on the
clinical scenario to evaluate, where information on OS,
progression-free survival (PFS), disease-free survival, the
hazard ratio, the response rate, quality of life, prognosis of
the condition and toxicity is considered and rated.8 In the
noncurative setting, treatments with an ESMO-MCBS grade
of 5 and 4 are considered to provide substantial clinical
benefit, whereas treatments with a grade <4 are not.8 In
present and future public health policy, this rating might
become more important to ensure access to these inno-
vative but expensive cancer drugs for the majority of pa-
tients. In this study, we aimed to systematically analyse
publicly available ESMO-MCBS information with a focus on
European Medicines Agency (EMA)-approved ICIs for met-
astatic solid tumours and describe the theoretical impact of
a threshold of ESMO-MCBS grade <4 on the availability,
health care outcome and cost-effectiveness of these cancer
drugs for Austrian cancer patients.MATERIALS AND METHODS
First, we defined the evaluation criteria for the investigated
studies on the background of the following points based on
publicly available information at the cut-off date of 31
December 2020: (i) all ICIs approved by the EMA; (ii) a
publicly available ESMO-MCBS grade from the ESMO-MCBS
Scorecard (https://www.esmo.org/guidelines/esmo-mcbs/
esmo-mcbs-scorecards); (iii) inclusion of studies covering
only metastatic solid cancers, namely, bladder, kidney, lung,
head and neck, breast, gastrointestinal and liver cancers;
and (iv) exclusion of haematological cancers and skin can-
cers (melanoma and Merkel cell carcinoma). ICI approvals
based on studies with an ESMO-MCBS grade <4 were
further investigated for cost-effectiveness as follows. In
addition to the ESMO-MCBS, we cross-validated the ICIs
with ESMO-MCBS <4 (i.e. low clinical benefit) using the
ASCO AVF. Recently, the threshold of clinical benefit was
published for the AVF. AVF scores <40 indicate low clinical




Costs were assessed within the context of the Austrian
health care system and included only direct medical drug
costs for ICIs. Accordingly, nonmedical direct costs2 https://doi.org/10.1016/j.esmoop.2021.100198[complication management, costs of comedications, intra-
venous drug administration, doctor consultation visits,
additional blood tests and testing for the programmed
death-ligand 1 (PD-L1) status] and indirect costs [loss of
economic output due to days missed from work (morbidity
costs) and premature death (mortality costs)] were not
taken into account. Incremental drug (e.g. ICIs) costs were
calculated as the difference between the total prices of
treatment under the addition of ICIs compared with those
of standard therapy. For each trial, incremental cancer drug
costs were calculated using the available average wholesale
price (AWSP or ‘Fabriksabgabepreis’) derived from the
Austrian ‘Warenverzeichnis’ and were cross-checked in the
local hospital pharmacy. We used the registrational trial’s
reported dosage protocols and median administered doses
(assuming an average patient with 70-kg body weight). For
atezolizumab, the costs were based on a dose of 840 mg
every 2 weeks (V3360 per dose) or 1200 mg every 3 weeks
(V47 992 per dose), and for durvalumab, the costs were
based on a dose of 1500 mg (V9264 per dose). For the
calculations of economic variables, we made the assump-
tion of a model with three health states, namely, PFS,
progressive disease (PD) and death.
For all treatment scenarios, we calculated the gain of life
years (LYs), the quality-adjusted life year (QALY) and the
incremental cost-effectiveness ratio (ICER). To calculate the
gain of LYs, we calculated the difference in the median OS
between the ICI-treated group and the standard of care
group. Basically, the QALY is a generic measure of disease
burden and includes both the quality and quantity of life
lived.9 To determine QALYs, we multiplied the health utility
(weight) value associated with a given state of health by the
years lived in that state. For instance, a year of life lived in
perfect health is worth 1 QALY [1 year of life years (LYs)  1
utility value]. The health utilities are numerical values that
represent an individual’s preferences for different health-
related outcomes, ranging from 0 (representing a state of
death) to 1 (representing a state of perfect health).9 Pre-
vious studies on metastatic breast cancer reported health
utility values of 0.715 for PFS and 0.443 for PD.10 For SCLC,
the reported health utility values were 0.673 for PFS and
0.473 for PD.11 Given these assumptions, we calculated the
QALY as follows: [median PFS (in years)  utility value PFS]
plus [median OS minus median PFS (in years)  utility value
PD]. The gain of QALY was calculated as the difference be-
tween the QALY of the ICI group and the QALY of the
standard of care group. The ICER was calculated by the in-
cremental costs divided by the gained LYs or the gained
QALY.
In addition to our calculations described above based on
median PFS/OS times, we developed a partitioned survival
model to simulate the clinical outcome and economic costs
for one ICI with ESMO-MCBS <4, according to data of the
CASPIAN trial.12 This trial compared the conventional
chemotherapy only with chemotherapy plus the ICI durva-
lumab. The chemotherapy only group received between
four and six (we averaged five cycles in the model) cycles
of platinumeetoposide. Patients presenting diseaseVolume 6 - Issue 4 - 2021
M. Pichler & J. Steyrer ESMO Openprogression or unacceptable adverse reactions received a
second-line treatment with topotecan. Our model structure
included the following three states: PFS, PD and death.
Time-to-event tables were used for the simulation and
assignment to a certain state. The primary outcomes of our
model simulation included total cost, QALYs and LYs. The
ICER was also calculated by the software.
Clinical efficacy data for the first-line treatments,
including the KaplaneMeier curves of PFS and OS, were
derived from the phase III CASPIAN study.12 The GetData
Graph Digitizer (version 2.26; http://www.getdata-graph-
digitizer.com/download.php) was used to extract the PFS
and OS probabilities from the PFS and OS curves of each
treatment group as previously described.13 The individual
patient data of each KaplaneMeier curve was reconstructed
and survival tables were used to fit the data. Distribution
functions were based on Weibull distribution [S(t) ¼
exp(ltg)] according to the suggestions of the TreeAge Pro
software. For the partitioned survival analysis-based cost-
effectiveness analysis, we calculated for the chemotherapy
only group five cycles of chemotherapy (according to the
CASPIAN study, 75% received carboplatin and 25% received
cisplatin).12 For the ICIs group durvalumab was calculated
for four cycles at a dose of 1500 mg every 21 days, followed
by continued use of durvalumab every 4 weeks for a median
of seven doses. We assumed for a body surface of 1.89 m2
that a one-cycle dose of the chemotherapy drugs included
cisplatin (80 mg/m2; costs per cycle: V68.4), carboplatin
area under the curve of 5 mg/ml/min (costs per cycle:
V136), etoposide 90 mg/m2 on days 1-3 of each cycle (costs
per cycle: V57.9), durvalumab (costs per cycle: V9264) and
for the second-line treatment upon progression topotecan
1.5 mg/m2/day on days 1-5 for each cycle (costs per cycle:
V1217). Patients in the immunotherapy group received four
cycles of chemotherapy (combined costs per cycle: V9441).
Analyses were conducted using a partitioned survival model
(Supplementary Figure S1, available at https://doi.org/10.
1016/j.esmoop.2021.100198) constructed with the Tree-
Age Pro 2021 software (TreeAge, Williamstown,
Massachusetts).
Potential patient numbers were retrieved from the pub-
licly available central registry of the Austrian Bureau of
Statistics (Statistik Austria).
RESULTS
EMA-approved ICIs and corresponding ESMO-MCBS grade
Overall, there are currently six EMA-approved ICIs available
for different types of metastatic solid tumours. These ap-
provals include the three PD-L1 inhibitors atezolizumab,
avelumab and durvalumab; the two PD1 inhibitors nivolu-
mab and pembrolizumab and the cytotoxic T-lymphocyte-
associated protein 4 inhibitor ipilimumab (Table 1). As
shown in Table 1, a total of 23 approved treatment settings
for these ICIs were identified in the publicly available ESMO-
MCBS Scorecard. Of the 23 different treatment settings, 19
were excluded from further cost-effectiveness evaluations:
15 had an ESMO-MCBS grade of 4, two bladder cancer
Volume 6 - Issue 4 - 2021approvals had not yet been graded (i.e. MCBS not available)
and two treatment settings in non-SCLC (atezolizumab in
combination with bevacizumab/chemotherapy14 and ipili-
mumab in combination with nivolumab/chemotherapy15)
have an alternative ICI-containing treatment approach with
an ESMO-MCBS grade 4 (pembrolizumab in combination
with chemotherapy16). Thus, for further cost-effectiveness
analyses, we selected three ICI-containing clinical sce-
narios in metastatic solid tumours identified with an ESMO-
MCBS grade <4 (i.e. not clinically significant according to
the ESMO definition): (i) in triple-negative breast cancer
(TNBC), the first-line atezolizumab approval (based on the
data of the IMpassion130 trial17) and (ii) in SCLC, the first-
line atezolizumab approval (based on the data of the
IMpower133 trial4) and (iii) the first-line durvalumab
approval (based on the data of the CASPIAN trial12). In
addition, we manually calculated an ASCO-based AVF score
<40 for all these three treatment scenarios, indirectly
confirming the low clinical benefit in another scoring
framework.Cost-effectiveness calculation of ICIs with ESMO-MCBS <4
To calculate the incremental drug (e.g. ICIs) costs compared
with standard of care treatment, we analysed the costs per
dose in the context of the clinical trial data. Table 2 shows a
study summary of these three treatment settings. In TNBC
patients, the median PFS observed with atezolizumabenab-
paclitaxel was 7.5 months compared with 5.0 months with
placeboenab-paclitaxel (difference 2.5 months). The most
recently updated clinical data from PD-L1-positive TNBC
patients showed a median OS duration of 25.4 months in
the atezolizumabenab-paclitaxel group and 17.9 months in
the placeboenab-paclitaxel group.17 The incremental drug
costs in Austria were V47 040 per patient, assuming a
median treatment duration of seven cycles (14 doses of
840 mg atezolizumab every 2 weeks).17 Cost-effectiveness
analysis of the use of atezolizumab in TNBC patients in
Austria led to an average gain of 0.625 LYs [difference in the
median OS (months) in the atezolizumabenab-paclitaxel
group and median OS (months) in the nab-paclitaxel only
group divided by 12], a QALY of 1.10 in the atezolizumabe
nab-paclitaxel group and a QALY of 0.77 in the chemo-
therapy only group, resulting in a gain of QALY of 0.33 per
person. These benefits were achieved at an incremental
cost of V47 040 per person (as calculated earlier). As a
result, the addition of atezolizumab to nab-paclitaxel was
associated with an ICER of V75 264 per LY gained and
V143 853 per QALY gained.
Concerning atezolizumab in SCLC patients, according to
the IMpower133 phase III study,18 the median PFS was 5.2
months in the atezolizumab/chemotherapy group and 4.3
months in the chemotherapy only group (difference 0.9
months), and the median OS was 12.3 months in the ate-
zolizumab group and 10.3 months in the placebo group
(difference ¼ 2 months).18 The incremental drug costs
in Austria were V33 593 per patient, assuming a median
number of atezolizumab doses of seven (1200 mghttps://doi.org/10.1016/j.esmoop.2021.100198 3
Table 1. Summary of EMA-approved immune checkpoint inhibitors in metastatic solid tumours, the corresponding publicly available ESMO-MCBS (https://
www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards) and potential immune checkpoint inhibitor alternatives with a higher ESMO-MCBS
Drug name Tumour type ESMO-MCBS Alternatives
Atezolizumab (Tecentriq) Bladder cancer first line n.a. Yes
Bladder cancer second line n.a. Yes
Non-small-cell lung cancer second Line 5 Yes
Non-small-cell lung cancer first line (combination with
chemotherapy and bevacizumab)
3 Yes
Small-cell lung cancer first line 3 No
Triple-negative breast cancer 3 No
Hepatocellular carcinoma 5 No
Avelumab (Bavencio) Renal cell carcinoma first line 3 Yes
Durvalumab (Imfinzi) Stage III non-small-cell lung cancer 4 No
Small-cell lung cancer 3 No
Nivolumab (Optivo) Non-small-cell lung cancer second line 5 Yes
Renal cell carcinoma second line 4 No
Renal cell carcinoma first line 4 Yes
Head and neck cancer second line 5 Yes
Oesophagus cancer second line 4 No
Pembrolizumab (Keytruda) Non-small-cell lung cancer second line 5 Yes
Non-small-cell lung cancer first line (combination
chemotherapy)
4 Yes
Non-small-cell lung cancer first line PD-L1 >50% 5 No
Renal cell carcinoma first line 4 Yes
Head and neck cancer first line 4-5 No
Head and neck cancer second line 4 Yes
Ipilimumab (Yervoy) Renal cell carcinoma first line (combination with
nivolumab)
4 Yes
Non-small-cell lung cancer first line (combination with
nivolumab and chemotherapy)
2 Yes
EMA, European Medicines Agency; ESMO, European Society for Medical Oncology; MCBS, Magnitude of Clinical Benefit Scale; n.a., not available.
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effectiveness analysis using data from the IMpower133
study showed an average gain of 0.17 LYs (difference in OS
in the atezolizumab group and OS in the standard of care
group divided by 12), a QALY of 0.57 in the atezolizumab/
chemotherapy group and a QALY of 0.48 in the chemo-
therapy only group, resulting in a gain of QALY of 0.09 per
person. These benefits were achieved at an incremental
cost of V33 593 in Austria. As a result, the addition of
atezolizumab to chemotherapy in SCLC was associated with
an ICER of V197 606 per LY gained and V373 256 per QALY
gained.
Regarding durvalumab in SCLC patients, the median PFS
was 5.1 months with durvalumab plus chemotherapy versus
5.4 months with chemotherapy only, and the median OS
was 13.0 months with durvalumab plus chemotherapy
versus 10.3 months with chemotherapy only (difference 2.7
months).12 The incremental drug costs with durvalumab
were V64 848 per patient, assuming a median number of
durvalumab doses of seven, as previously described.12Table 2. Clinical benefit scores and incremental cancer drug costs for immune ch
an ESMO-MCBS of <4
Setting/trials name Experimental/control arm
TNBC/IMpassion130 Atezolizumab plus nab-paclitaxel/nab-paclitaxel
SCLC/IMpower133 Atezolizumab plus carboplatin-etoposide/carboplatin-
etoposide
SCLC/CASPAN Durvalumab plus platinum-etoposide/platinum-etoposide
ESMO, European Society for Medical Oncology; MCBS, Magnitude of Clinical Benefit Scale;
4 https://doi.org/10.1016/j.esmoop.2021.100198Cost-effectiveness analysis of the CASPIAN study showed
an average gain of 0.23 LYs (difference in OS in the durva-
lumab group and OS in the chemotherapy only group
divided by 12), a QALY of 0.60 in the durvalumab/chemo-
therapy group and a QALY of 0.49 in the chemotherapy only
group, resulting in a gain of QALY of 0.11 per person. These
benefits were achieved at an incremental cost of V64 848
per patient. As a result, the addition of durvalumab to
chemotherapy in SCLC was associated with a deterministic
base-case ICER of V281 948 per LY gained and V589 527
per QALY gained.
Applying partitioned survival analysis-based cost-effec-
tiveness calculations (Supplementary Figures S2 and S3,
available at https://doi.org/10.1016/j.esmoop.2021.100
198), we found in the durvalumab/chemotherapy group
incremental drug costs of V50 331 per patient (V53 765
per patient versus V343 444 per patient in the chemo-
therapy only group), and a gain of QALY of 0.15 per person
(0.77 QALYs in the durvalumab/chemotherapy group and
0.62 QALYs in the chemotherapy only group). Overall,eckpoint inhibitors across different settings in metastatic solid tumours with
ESMO-MCBS Treatment doses, median Costs per dose/incremental costs
3 14 V3360/V47 040
3 7 V47 992/V33 593
3 7 V9264/V64 848
SCLC, small-cell lung cancer; TNBC, triple-negative breast cancer.
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Figure 1. Cost-effectiveness analysis comparing chemotherapy only with addition of Durvalumab. Incremental costs per QALY are shown (derived from TreeAge
Pro Software package). QALY, quality-adjusted life year.
M. Pichler & J. Steyrer ESMO Opendurvalumab/chemotherapy as the first-line treatment for
SCLC had an ICER of V336 534 per QALY compared with
chemotherapy only treatment (Figure 1).Potential cost-saving effects in the Austrian population
Finally, to calculate the potential cost-saving effect based on
the assumption that the entire Austrian target population of
patients with metastatic solid tumours of ESMO-MCBS
grade <4 will be not treated with ICIs (as discussed
earlier), we next estimated the putative size of the target
population (i.e. patients with metastatic TNBC and exten-
sive SCLC). The incidence rate of breast cancer has been
relatively stable within the last 10 years, with w5500 newly
diagnosed breast cancer cases in Austria (Supplementary
Figure S4, available at https://doi.org/10.1016/j.esmoop.
2021.100198). Of these, w15% of cases were diagnosed
as the TNBC subtype (n ¼ 825). Taking into account that
~5%19 of cases are diagnosed as metastatic TNBC at the
time of diagnosis (n ¼ 41) and up to 40%20 of primarily
localized stage I-III TNBC cases (n ¼ 784) recur within 5
years (n ¼ 314), the number of metastatic TNBC cases per
year is estimated to be w355. According to the atezolizu-
mab registrational trial IMpassion130,17 41% of TNBC pa-
tients are PD-L1 1% positive, a requirement for the
administration of this drug. Thus, we estimated for our cost
calculation model the number of potentially metastatic PD-
L1-positive TNBC patients to be w146 per year in Austria.
Of these, we estimated the proportion of immunotherapy-
ineligible patients (older age, comorbidities, performance
status and comedications) in this rather young patient
cohort to be w10%, resulting in an absolute number of 130
TNBC patients per year.
The lung cancer incidence in Austria in 2017 was 4676
(2739 males and 1937 females, Supplementary Figure S5,
available at https://doi.org/10.1016/j.esmoop.2021.100198),
and w15%21 of the patients (n ¼ 700) were diagnosed with
SCLC. Of these SCLC patients, w70%22 were diagnosed
primarily with extensive SCLC (n¼ 490) and were considered
Volume 6 - Issue 4 - 2021for upfront palliative combination therapy with platinum/
etoposide plus atezolizumab or durvalumab. However, as a
substantial number of SCLC patients carry relevant comor-
bidities, are in an advanced disease state, exhibit a reduced
performance status and are aged >75 years, many of them
fail to receive this standard regimen.23 Although systematic
data on the percentage of combination therapy-ineligible
patients in Austria are not available, in our experience, we
estimate thatw50% of patients with extensive SCLC will not
qualify for combination immunochemotherapy. Thus, we
used an estimated patient number of 350 per year with
extensive SCLC who were eligible for combination therapy in
Austria.
The savings potential for ruling out drugs with an ESMO-
MCBS grade <4 was extrapolated over the yearly incidence
and potential size of the target population of TNBC and
SCLC patients in Austria (according to the formula AWSP
multiplied by cases per year). By applying the ESMO-MCBS,
a savings benefit from V6.1 million (for atezolizumab in
TNBC) up to V11.7 million (atezolizumab in SCLC) or V22.7
million (durvalumab in SCLC) can be reached.DISCUSSION
The ESMO-MCBS was introduced as a tool to aid in clinical
decisions and to identify novel cancer drugs with a gradu-
ation depending on the robustness, availability and rele-
vance of clinical trial-generated data.7 Thus, a grade 4 has
been defined as a treatment setting with significant clinical
benefit.7 In our analysis, after applying the criteria defined
in the ‘Methods’ section we found that 3 of 23 (13%)
currently approved treatment approaches for metastatic
solid tumours had no significant clinical benefit (ESMO-
MCBS grade <4). First, this is good news, as for the majority
of ICI treatment schedules, solid and high-quality clinical
results led to the definition of ‘significant clinical benefit’.
This underlines the impact that these new drugs have on
improving meaningful clinical endpoints, improving quality
of life, or reducing toxicity compared with classic cytotoxichttps://doi.org/10.1016/j.esmoop.2021.100198 5
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scenarios with an ESMO-MCBS grade <4 are challenging
types of cancer. For instance, metastatic TNBC commonly
affects premenopausal young women and is associated with
an aggressive clinical course, a high disease burden, high
morbidity and a poor prognosis due to a significant lack of
other treatment options.24 Unfortunately, disseminated
SCLC patients have a median OS of 6-10 months, with no
new cancer drug approved within the last 20 years.23
According to our analysis, atezolizumab combined with
nab-paclitaxel for metastatic TNBC is not cost-effective in
Austria from the perspective of different definitions: The
NICE (UK) threshold for what is considered an acceptable
value ranges between GB£20 000 and GB£30 000
(or wUS$30 000e45 000), and the American College of
Cardiology/American Heart association used the WHO
benchmark that is based on a country’s gross domestic
product (GDP) per capita.25 Services that exceed three times
GDP per capita are viewed as economically unattractive
(based on the 2020 Austrian GDP, which is approximately
>V150 000 per QALY; https://www.worlddata.info/europe/
austria/economy.php). In our study, the incremental cost of
atezolizumab for TNBC patients was V47 040, the incre-
mental QALY was 0.11 and the ICER was V143 853 per
QALY. The first cost-effectiveness analysis of atezolizumab in
TNBC patients was performed by Weng et al.,13 who re-
ported that for the United States, the ICER value was
US$229 359.88 per QALY gained for the PD-L1-positive
population, and in China, the ICER value was US$72
971.88 per QALY gained. The authors concluded that the
use of atezolizumab was not cost-effective at the
willingness-to-pay thresholds of US$150 000 per QALY in
the United States and US$29 383 per QALY in China. Li
et al.26 reported an ICER of $361 218 per QALY gained in the
PD-L1-positive subgroup and concluded again that atezoli-
zumab is not cost-effective in these patient populations. The
latest economic analysis was performed by Phua and col-
leagues,27 who reported an additional gain of 0.361 QALYs
(0.636 LYs) at an ICER of US$324 550 per QALY gained. In
summary, all studies evaluating atezolizumab as a first-line
treatment for TNBC describe poor cost-effectiveness in
different countries and continents, underlining the neces-
sity for improved price models to ensure broad access to
this new treatment approach.
According to our analysis, atezolizumab combined with
platinum/etoposide for extensive SCLC is not cost-effective
in Austria from the perspective of the aforesaid definition.
The incremental cost per patient was V33 593, the incre-
mental QALY was 0.09 and the ICER was V373 253 per
QALY. In line with our findings, the first report by Zhou and
colleagues11 showed that treatment with atezolizumab plus
chemotherapy was estimated to increase costs by US$52
881 compared with chemotherapy alone, with a gain of
0.10 QALYs, leading to an incremental cost-effective ratio of
US$528 810 per QALY. Similar findings were reported in a
cost-effectiveness analysis in a study from China, where the6 https://doi.org/10.1016/j.esmoop.2021.100198authors concluded that atezolizumab combination therapy
was not more cost-effective than chemotherapy alone at a
world trade product threshold of US$25 929 per QALY.28
According to our analysis, durvalumab combined with
platinum/etoposide for extensive SCLC is not cost-effective
in Austria from the perspective of the definitions in the
United Kingdom, United States and WHO. The incremental
cost per patient was US$64 848, the incremental QALY was
0.11 and the ICER was V589 527 per QALY. Although a
comparison with other health care systems is difficult,
Zhang and colleagues29 applied a partitioned survival model
and calculated the price of the same treatment setting on
the basis of the Medicare drug average sales price from the
US Centers for Medicare & Medicaid. They reported an in-
cremental cost per patient of US$78 019, while the incre-
mental QALY was 0.220, and the ICER was US$355 448.86
per QALY.29 Expanding this view to the Chinese health care
system, Liu and Kang30 reported that durvalumab plus
chemotherapy yielded additional 0.25 QALYs, with incre-
mental costs of US$76 354, resulting in an ICER of US$302
051 per QALY compared with chemotherapy alone. Even
when patient assistant program was available, the ICER was
US$192 591 per QALY, leading the authors to conclude that
durvalumab in SCLC first-line treatment will be unlikely to
be cost-effective in China. Similar findings were reported in
our partitioned survival analysis done for the CASPIAN trial:
the durvalumab/chemotherapy group incremental drug
costs of V50 331 per patient, and a gain of QALY of 0.15 per
person, with an ICER of V336 534 per QALY compared with
chemotherapy only treatment. Vogler et al.31 compared the
prize of 31 cancer drugs in 18 different countries including
16 different European countries. The difference of a drug
official undiscounted price between the highest priced
country and the lowest priced country varied between 28%
and 388%. Similar findings showing a high degree of cancer
drug cost variation were reported in a survey of 15 Euro-
pean countries.32 Thus, our approach and findings are
applicable to other European countries, though it strongly
depends on the country-specific drug prize and (unre-
ported) discounts.
In our model, we determined the cost and utility of first-
line durvalumab for only seven doses, as this was the me-
dian dosage reported in the CASPIAN trial. Nevertheless,
Zhang et al.29 analysed cost-effectiveness not only for seven
doses but also for 1 year, 2 years and a lifetime to avoid the
influence of the duration of durvalumab, and their results
indicated that the durvalumab plus chemotherapy regimen
is not economical in all evaluated situations. The authors
also concluded that durvalumab combined with chemo-
therapy was not a cost-effective approach, consistent with
the results of our study on the Austrian system.
The findings for both atezolizumab and durvalumab
in extensive SCLC and their disappointing cost-
effectiveness are in contrast to those for pembrolizumab
in the first-line treatment of NSCLC, where the PD1 in-
hibitor pembrolizumab with or without chemotherapy hasVolume 6 - Issue 4 - 2021
M. Pichler & J. Steyrer ESMO Openbeen suggested to be a cost-effective option as a first-line
treatment for metastatic NSCLC expressing high levels of
PD-L1.33 Generally, predictive biomarkers might help to
enrich patients with a high probability of responding and
therefore decrease the ICER and increase the gain of
QALYs. Nevertheless, according to the IMpower133 trial, in
SCLC, PD-L1 is either not frequently expressed or its
tumour mutational burden (another hypothetical predic-
tive biomarker) cannot be successfully validated as
useful.4
In its most recently updated report for 2020-2023, the
Institute of Clinical and Economic Review (ICER) recom-
mended cost-effectiveness thresholds with a maximum
between US$100 000 and US$150 000 per QALY (https://
icer.org/our-approach/methods-process/value-assessment-
framework). None of our scenarios fulfilled these criteria,
and cost-effectiveness for the ESMO-MCBS grade <4 ICI
treatment schedules in Austria has to be refused. Finally,
the low clinical benefit of these three treatment scenarios
could also be confirmed in the ASCO-based AVL framework
(AVL score <40). In addition to the ESMO and ASCO
framework, the NCCN has established an NCCN Framework
for Resource Stratification of NCCN Guidelines (NCCN
Framework) tool, which defines appropriate treatment
pathways based on available resourcesdBasic, Core,
Enhanced, and NCCN Guidelines (https://www.nccn.org/
guidelines/nccn-framework-for-resource-stratification-of-nccn-
guidelines). This framework might be another resource for
different countries in decision making to select cost-
efficient treatment schedules.
Our study is not without limitation. Our analyses were
based on three clinical trials in which patients were
generally younger and experienced a longer survival time
than those in clinical real-world scenarios. Next, we used
the whole sale price (Fabriksabgabepreis) to estimate the
drug costs. Health care providers (hospitals) in Austria are
contracting discounts, risk share agreements and financial
caps with pharmaceutical companies, but the lack of pub-
licly available sources reporting contracts poses challenges
in the usage of the whole sale price for cost-effectiveness
analyses. The real costs for ICIs will be quite lower than
the price calculations of our analyses. By contrast, costs
increase with the use of ICIs through the surveillance of
side-effects, expanded laboratory tests to detect immune-
related side-effects and hospitalization due to complica-
tion management and severe adverse events.
Despite the mentioned limitations, the results of these
analyses suggest an ESMO-MCBS grade <4 to reflect high
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